LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal PathLabs reported Q4 FY26 revenue of Rs. 703 crore (up 16.6%) and FY26 revenue of Rs. 2,763 crore (up 12.2%), driven by 12.9% sample volume growth in Q4. EBITDA for FY26 stood at Rs. 752 crore with a margin of 27.2%, while PAT was Rs. 510 crore at 18.4% margin. The company acquired Shahbazkers Diagnostic Centre in Mumbai for Rs. 20 crore (3.3x revenue) to strengthen its West region presence. Management guided for early to mid-teens (13%-15%) revenue growth in FY27 with margins expected to stay in the 27%-28% range as investments in infrastructure and lab expansion continue. The company added 14 new labs and over 1,100 collection centers during the year, with FY27 capex planned at Rs. 100-120 crore. A new Dubai subsidiary was incorporated for international expansion over the next 3-5 years.
Dr. Lal PathLabs demonstrated strong Q4 performance with 16.6% revenue growth. Management guided for sustained early to mid-teens growth in FY27 but explicitly stated margins are not expected to expand beyond 27%-28% as investments continue. The company maintains a robust net cash position of Rs. 1,526 crore, enabling both organic growth and M&A opportunities.